The anti-infective agents market is expected to grow from US$ 1,35,961.03 million in 2022 to US$ 1,64,196.61 million by 2028; it is estimated to grow at a CAGR of 3.19% from 2022 to 2028.
Anti-infectives are medications that help in preventing and treating infections, such as anti-bacterial, anti-viral, anti-fungal, and antiparasitic medications. Anti-infective therapies help in the treatment of minor infections and many serious infectious diseases tuberculosis or pneumonia. These therapies have revolutionized healthcare as they enrich and extend the life of patients suffering from all types of infectious diseases.
Download sample PDF Copy at: https://www.theinsightpartners.com/sample/TIPRE00004201/
Abbott; Allergan Plc.; Astellas Pharma Inc.; Merck & Co., Inc.; Bayer AG; Bristol-Myers Squibb Company; Boehringer Ingelheim International GmbH; F. HOFFMANN-LA ROCHE Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline plc.; and Novartis AG are the leading companies operating in the global anti-infective agents market.
According to WHO, in many regions, cancer is the second-largest cause of death. Digestive malignancies account for a significant fraction of all tumors, and their occurrence is predicted to rise faster than other tumor types due to bad lifestyle habits. The information obtained by THz-based scanning can prove beneficial in the care of cancer patients and, more crucially, in the early diagnosis of various solid tumors, because it can correctly differentiate between different types of molecules based on water content. According to GLOBOCAN, 19.3 million new cancer cases were reported in 2020, with ~10.0 million cancer deaths. In 2018, ~4.8 million new instances of gastrointestinal (GI) malignancies were diagnosed worldwide, with 3.4 million deaths. GI malignancies are responsible for 26% of global cancer incidence and 35% of cancer-related deaths. Recent advancements in medical imaging can substantially lead to improvements in the early detection and treatment of various clinical disorders. THz imaging devices can also aid in detecting early cancer before it becomes apparent or detectable by other means.
The anti-infective agents market is segmented into type, range, route of administration, indication, distribution channel, and geography. Based on type, the market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. Based on range, the anti-infective agents market is bifurcated into narrow spectrum and broad spectrum. Based on route of administration, the anti-infective agents market is segmented into IV, oral, topical, and others. Based on indication, the anti-infective agents market is segmented into HIV, tuberculosis, respiratory infection, pneumonia, and others. Based on distribution channel, the anti-infective agents market is categorized into hospital pharmacies, retail pharmacies, specialty pharmacies, e-commerce, and others.
Inquiry Before Buying at: https://www.theinsightpartners.com/speak-to-analyst/TIPRE00004201
North America is expected to hold the largest share in the anti-infective agents market during the forecast period. The US held the largest market for anti-infective agents in the North American region, and the market in this region is expected to grow due to factors such as the highest incidence rate of infectious diseases and rapid developments by the market players in the region. The anti-infective agents market in the US is expected to grow from US$ 36,084.54 Mn in 2022 to US$ 44,385.57 Mn by 2028, at a CAGR of 3.5% during 2022–2028. The US healthcare system is witnessing massive investments and new product introductions. Further, the majority number of players are engaged in business activities such as sales and research partnerships, innovation, and product approvals.
For instance, in July 2020, Merck & Co. unveiled its plan to begin two large clinical trials in September of an experimental oral anti-viral therapy, MK-4482, for Covid-19. Similarly, in April 2020, Abbott has launched its third test for coronavirus (COVID-19) and is shipping tests to hospitals across the US. This new test is a lab-based serology blood test for the discovery of the antibody, IgG that detects if a person has had the novel coronavirus (COVID-19). This antibody test adds to Abbott’s existing COVID-19 tests that are already being utilized, comprising its m2000 molecular laboratory system and its ID NOW molecular point-of-care device. Further, experimental shots are expected to be studied in humans this year. Such strategic factors will eventually offer significant growth for the US anti-infective agents market by 2028.
Below is the list of the growth strategies done by the players operating in the anti-infective agents market:
In Jun-2022 – Merck’s VAXNEUVANCE drug for Prevention of Invasive Pneumococcal Disease in Infants and Children was approved by U.S. FDA
Feb-2022 – Roche has announced the expansion of the COVID-19 PCR portfolio to the cobas 5800 System, a recently launched molecular laboratory instrument, in countries accepting the CE mark. These include cobas SARS-CoV-2 Qualitative and cobas SARS-CoV-2 & Influenza A/B tests.
Apr-2022 – FDA has approved Gilead Sciences’ supplemental new drug application for Veklury (remdesivir) for the treatment of pediatric patients under 12 years with COVID-19
Apr-2022 – Sandoz, a Novartis Division announced its extension of collaboration agreement with Ares Genetics (Ares), aimed at driving cutting-edge digital solutions in the global fight against antimicrobial resistance (AMR).
Purchase a Copy of this Report: https://www.theinsightpartners.com/buy/TIPRE00004201/
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi